Avalo Therapeutics, Inc. - Common Stock (AVTX)
CUSIP: 05338F306
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 22,946,429
- Total 13F shares
- 75
- Share change
- +75
- Total reported value
- $1,253
- Price per share
- $16.71
- Number of holders
- 1
- Value change
- +$1,253
- Number of buys
- 1
Quarterly Holders Quick Answers
What is CUSIP 05338F306?
CUSIP 05338F306 identifies AVTX - Avalo Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 05338F306:
Top shareholders of AVTX - Avalo Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
|
Company |
9.9%
|
1,939,065
|
$32,867,152 | +$9,371,621 | 31 Dec 2025 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
10%
|
1,904,257
|
$32,277,156 | +$7,561,497 | 31 Dec 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
12%
|
2,125,819
|
$31,058,216 | $0 | 27 Feb 2026 | |
| BVF INC/IL |
13F
|
Company |
5.9%
|
1,355,257
|
$24,611,467 | — | 31 Dec 2025 | |
| Logos Global Management LP |
13D/G
|
— |
5.6%
|
1,285,000
|
$23,104,300 | $0 | 26 Mar 2026 | |
| Nantahala Capital Management, LLC |
13F
13D/G
|
Company |
9.4%
from 13D/G
|
1,235,000
|
$22,427,600 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
13D/G
|
Company |
6.4%
from 13D/G
|
1,187,300
|
$21,561,368 | — | 31 Dec 2025 | |
| Affinity Asset Advisors, LLC |
13F
13D/G
|
Company |
5.7%
from 13D/G
|
1,051,054
|
$19,087,141 | — | 31 Dec 2025 | |
| Caligan Partners LP |
13F
13D/G
|
Company |
4.9%
from 13D/G
|
881,533
|
$16,008,639 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
|
Company |
5%
|
934,429
|
$14,726,601 | +$743,163 | 17 Feb 2026 | |
| VANGUARD GROUP INC |
13D/G
13F
|
The Vanguard Group · Company |
4.4%
|
804,084
|
$14,602,165 | +$2,023,878 | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
13D/G
|
Company |
3.5%
from 13D/G
|
627,502
|
$11,395,436 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
2.7%
|
621,350
|
$11,283,716 | — | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.4%
|
550,000
|
$9,988,000 | — | 31 Dec 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
13D/G
|
Company |
2.8%
from 13D/G
|
524,436
|
$9,523,758 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2.2%
|
507,550
|
$9,217,107 | — | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13D/G
13F
|
Company |
3.8%
|
711,967
|
$9,049,101 | -$6,100,673 | 30 Sep 2025 | |
| Commodore Capital LP |
13F
|
Company |
2.1%
|
483,000
|
$8,771,280 | — | 31 Dec 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
2.1%
|
483,000
|
$8,771,280 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
2.1%
|
477,816
|
$8,677,138 | — | 31 Dec 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
2.1%
|
475,625
|
$8,637,350 | — | 31 Dec 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1.9%
|
441,978
|
$8,026,320 | — | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
13D/G
|
Company |
2.4%
from 13D/G
|
439,312
|
$7,977,906 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.8%
|
419,491
|
$7,617,957 | — | 31 Dec 2025 | |
| Patient Square Capital LP |
13F
|
Company |
1.4%
|
311,966
|
$5,665,303 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
1.3%
|
289,571
|
$5,258,610 | — | 31 Dec 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.2%
|
275,000
|
$4,994,000 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.2%
|
264,907
|
$4,810,711 | — | 31 Dec 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
1.1%
|
263,642
|
$4,787,739 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.95%
|
217,974
|
$3,958,408 | — | 31 Dec 2025 | |
| Jain Global LLC |
13F
|
Company |
0.95%
|
217,292
|
$3,946,023 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.92%
|
210,994
|
$3,831,651 | — | 31 Dec 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.88%
|
202,127
|
$3,670,626 | — | 31 Dec 2025 | |
| Patrick J. Crutcher |
13D/G
|
— |
4.2%
|
549,467
|
$3,593,514 | $0 | 06 Aug 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.86%
|
197,747
|
$3,591,086 | — | 31 Dec 2025 | |
| SummitTX Capital, L.P. |
13F
|
Company |
0.85%
|
195,873
|
$3,557,054 | — | 31 Dec 2025 | |
| NAN FUNG TRINITY (HK) Ltd |
13F
|
Company |
0.82%
|
189,000
|
$3,432,240 | — | 31 Dec 2025 | |
| Garry Arthur Neil |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
440,981
mixed-class rows
|
$3,322,999 | — | 28 Mar 2026 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.78%
|
178,855
|
$3,248,007 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.72%
|
166,152
|
$3,018,294 | — | 31 Dec 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.67%
|
153,313
|
$2,784,164 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.65%
|
150,000
|
$2,724,000 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.65%
|
148,237
|
$2,691,984 | — | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.61%
|
139,667
|
$2,536,353 | — | 31 Dec 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.59%
|
135,552
|
$2,461,624 | — | 31 Dec 2025 | |
| MOODY ALDRICH PARTNERS LLC |
13F
|
Company |
0.58%
|
133,231
|
$2,419,475 | — | 31 Dec 2025 | |
| Squadron Capital Management LLC |
13F
|
Company |
0.57%
|
130,000
|
$2,360,800 | — | 31 Dec 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.54%
|
124,666
|
$2,263,935 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.46%
|
105,814
|
$1,921,582 | — | 31 Dec 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.42%
|
95,631
|
$1,736,659 | — | 31 Dec 2025 |
Institutional Holders of Avalo Therapeutics, Inc. - Common Stock (AVTX) as of Q1 2026
As of 31 Mar 2026,
Avalo Therapeutics, Inc. - Common Stock (AVTX) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
75 shares.
The largest 1 holders included
Farther Finance Advisors, LLC.
This page lists
1
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
84
Q1 2026 holders
1
Holder diff
-83
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.